Egrifta (Tesamorelin) Compounding Pharmacy and FDA Enforcement: What Every Woman Needs to Know

What Egrifta (Tesamorelin) Actually Is and Why Women Are Asking About It

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates pulsatile growth hormone (GH) secretion. The brand Egrifta was approved by the FDA in November 2010 specifically to reduce excess visceral abdominal fat in HIV-positive adults on antiretroviral therapy. That approval has never been extended to the general population, to women seeking body recomposition, or to any anti-aging indication.

Despite that narrow approval, tesamorelin has circulated widely through compounding pharmacies and online peptide vendors since roughly 2018. Women in perimenopause and post-menopause are a growing share of the off-label market, partly because GH secretion declines with age and partly because visceral fat accumulation accelerates after the final menstrual period. That interest is understandable. The enforcement and quality picture around compounded tesamorelin, however, is genuinely complicated.

Why Women Are Particularly Interested After Menopause

Estrogen modulates the GH-IGF-1 axis in multiple ways. Premenopausal women have higher GH pulse frequency than age-matched men, but after menopause GH secretion falls sharply. One pituitary research review found that postmenopausal women on oral estrogen actually blunt hepatic IGF-1 production, meaning the route of estrogen delivery changes how any GH-stimulating peptide behaves in your body. Women on oral hormone therapy may see a blunted IGF-1 response to tesamorelin compared with women using transdermal estradiol or no estrogen at all. No compounding pharmacy advertisement will tell you this.

The Off-Label Use Field

Women seeking tesamorelin off-label are typically looking for visceral fat reduction, improved lean mass, or better sleep quality. The only randomized, placebo-controlled data on visceral fat reduction in non-HIV populations come from small investigator-initiated trials. A 2010 NEJM trial by Falutz et al. in HIV-positive adults showed a 15.2% reduction in visceral adipose tissue at 26 weeks, but this enrolled predominantly men. Female-specific efficacy and safety data in the off-label setting are essentially absent from the published literature.

FDA and Federal Regulatory Framework for Tesamorelin

The FDA regulates compounded drugs under two distinct legal pathways, and tesamorelin sits uneasily in both of them.

503A Compounding Pharmacies (Patient-Specific)

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound a drug for an individual patient based on a valid prescription from a licensed practitioner. The compounder must not copy a commercially available product without clinical justification. Because Egrifta is commercially available (for its approved indication), a 503A pharmacy compounding tesamorelin for a non-HIV patient is legally vulnerable. The FDA has stated that copying an approved drug without demonstrating a clinical difference (e.g., a different dose form or concentration needed for that specific patient) does not qualify for 503A exemptions.

503B Outsourcing Facilities

503B outsourcing facilities can compound drugs without individual prescriptions and can sell to hospitals and clinics at scale, but they must register with the FDA and follow current Good Manufacturing Practices (cGMP). Tesamorelin is not on the FDA's list of bulk drug substances that can be used in compounding under 503B. That means a 503B facility producing tesamorelin for general distribution is doing so outside any recognized legal authorization.

The Nominated Substances List

The FDA maintains a list of bulk drug substances under evaluation for 503B compounding eligibility. Tesamorelin has been nominated for this list by compounders, but as of the FDA's most recent bulk substances update, it has not been added to Category 1 (substances that may be compounded) or Category 2 (substances that may not). It remains in an undecided limbo, which some pharmacies have interpreted as tacit permission. The FDA has explicitly said that being on the nominated list does not confer any right to compound.

FDA Warning Letters and Enforcement Actions Against Tesamorelin Compounders

The FDA's enforcement posture toward peptide compounders intensified in 2023 and 2024. Warning letters went to multiple facilities for a cluster of related violations.

What the Warning Letters Said

In FDA Warning Letters issued in 2023-2024 to compounding pharmacies, the agency cited:

• Compounding copies of approved drugs (Egrifta/tesamorelin, semaglutide) without medical necessity documentation
• Selling injectable peptides without valid prescriptions or to non-patient customers
• Failure to meet sterility standards under USP <797> (the chapter governing sterile compounding)
• Mislabeled products listing incorrect concentrations or excipients
• Distribution of drug products bearing false or misleading claims about FDA approval status

Some of these letters resulted in voluntary recalls. Others led to consent decrees restricting production.

State Board Actions

State pharmacy boards operate independently of the FDA and have their own enforcement histories. The California State Board of Pharmacy, Texas State Board of Pharmacy, and Florida Department of Health have each issued cease-and-desist orders or license suspensions to compounders selling injectable peptides, including tesamorelin, without proper sterile-compounding certification or valid prescriptions. Women sourcing tesamorelin should verify, at minimum, that any pharmacy holds an active license in the state where it is physically located and in the state where you reside.

The "Research Chemical" Workaround

A parallel market sells tesamorelin labeled "for research use only, not for human use." This label is a legal fiction designed to avoid FDA jurisdiction over human drugs. These products are unregulated, untested for human safety, and not manufactured under any pharmaceutical standard. The FDA has explicitly warned that purchasing these products for personal use carries serious risk of contamination, incorrect dosing, and unknown long-term harm. Research-grade tesamorelin is not safe for self-administration. Full stop.

Quality Standards: What to Test For and Why It Matters for Women

If you are working with a clinician who has determined that compounded tesamorelin is clinically appropriate for your specific situation, quality verification is not optional.

HPLC Purity

High-Performance Liquid Chromatography (HPLC) measures chemical purity. For a peptide intended for injection, purity should be ≥98% by HPLC. Impurities in growth-hormone-releasing peptides can include truncated sequences, oxidized methionine residues, or synthesis byproducts. Some of these impurities are immunogenic. In women, who tend to mount stronger innate immune responses than men, immunogenic peptide impurities carry a real (if poorly quantified) risk of anti-drug antibodies that could neutralize efficacy or cause injection-site reactions.

Sterility and Endotoxin Testing

Injectable compounds must pass sterility testing per USP <71> and endotoxin testing per USP <85>. Acceptable endotoxin limits for a peptide administered subcutaneously are typically <5 EU/mg. Endotoxin (pyrogen) contamination causes fever, rigors, and systemic inflammation. Women in perimenopause who are already experiencing vasomotor symptoms may find that even low-grade endotoxin reactions are difficult to distinguish from hot flashes, which delays recognition of a quality problem.

Certificate of Analysis

Any legitimate compounding pharmacy should provide a Certificate of Analysis (CoA) from an independent, DEA-registered testing laboratory. The CoA should include lot number, HPLC purity, sterility result, endotoxin result, and potency confirmation. If a pharmacy refuses to share a CoA or provides one from an in-house lab without independent verification, that is a disqualifying red flag.

PCAB Accreditation

The Pharmacy Compounding Accreditation Board (PCAB), administered by ACHC, is the primary voluntary accreditation body for U.S. Compounding pharmacies. PCAB accreditation requires on-site audits, adherence to USP <797> and USP <795> standards, and staff training verification. Fewer than 1% of U.S. Compounding pharmacies hold this credential. It does not guarantee legal authorization to compound tesamorelin, but it meaningfully reduces the risk of sterility failures.

Pregnancy, Lactation, and Contraception: A Required Section

Tesamorelin is contraindicated in pregnancy. This is not a precautionary statement. It reflects findings from animal reproductive studies. The Egrifta prescribing information carries a pregnancy warning based on embryofetal toxicity in animal data, and tesamorelin has not been studied in pregnant women.

Why This Matters Across Life Stages

• Reproductive years. Women who are not using reliable contraception should not use tesamorelin. Because GH-axis peptides can alter insulin sensitivity and potentially affect ovulatory regularity in women with already-irregular cycles, the interaction with fertility is unpredictable. Women with PCOS are particularly vulnerable to GH-axis manipulation, given their already-elevated IGF-1 levels in many phenotypes. PCOS affects approximately 8-13% of reproductive-age women, and tesamorelin has not been studied in this population.

• Trying to conceive. Stop tesamorelin before attempting conception. The washout period is not formally established in published literature, but given the peptide's short half-life (approximately 26-38 minutes for the native molecule), most clinicians recommend discontinuing at least one full menstrual cycle before attempting pregnancy.

• Pregnancy. Contraindicated. If you become pregnant while using compounded tesamorelin, stop immediately and contact your obstetric provider.

• Postpartum and lactation. No human lactation transfer data exist for tesamorelin. Given that GH-axis peptides are biologically active and that the consequences of GH-axis disruption in a nursing infant are unknown, tesamorelin use during breastfeeding is not recommended. This is a straightforward risk-benefit judgment in the absence of safety data.

• Perimenopause. This is the life stage where off-label interest is highest. Vasomotor symptoms, weight redistribution toward visceral fat, and sleep disruption are all real concerns that tesamorelin's mechanism could theoretically address. But the interaction with declining estrogen, fluctuating FSH/LH, and any concurrent hormone therapy has not been studied. Women on systemic hormone therapy should be aware of the oral estrogen-IGF-1 blunting effect described above.

• Post-menopause. Same considerations as perimenopause, with the additional note that older women have higher baseline cardiovascular risk and that GH excess is associated with increased IGF-1, which carries theoretical cancer-promotion concerns at sustained supraphysiologic levels.

Who This May Be Appropriate For and Who It Is Not

The following framework is developed by the WomanRx clinical team to help women and their prescribers think through tesamorelin appropriateness by life stage and condition, given the current evidence gap.

Women for Whom the Risk-Benefit May Justify Further Conversation with a Clinician

• HIV-positive women with confirmed lipodystrophy, where brand Egrifta is the FDA-indicated option
• Postmenopausal women with documented adult GH deficiency confirmed by stimulation testing (an endocrinology evaluation, not a wellness-clinic questionnaire)
• Women whose prescribing clinician has performed baseline IGF-1, fasting glucose, and HbA1c testing, and who will monitor these quarterly

Women for Whom Compounded Tesamorelin Is Unlikely to Be Appropriate

• Any woman who is pregnant, trying to conceive, or breastfeeding
• Women with active malignancy or a personal history of hormone-sensitive cancer, given IGF-1's role in cell proliferation
• Women with uncontrolled type 2 diabetes (tesamorelin can raise fasting glucose)
• Women with PCOS who have not had GH-axis evaluation, given existing IGF-1 dysregulation in many PCOS phenotypes
• Women sourcing it from a non-prescribing wellness platform without baseline labs

How to Choose a Pharmacy for Egrifta (Tesamorelin)

Assuming you have a valid prescription from a licensed clinician and a documented clinical rationale, these are the minimum standards a compounding pharmacy should meet before you accept a vial.

Verification Checklist

1. Active state pharmacy license in both the pharmacy's home state and your state of residence. Verify via your state board's public license lookup tool.
2. Valid DEA registration for controlled substances (tesamorelin itself is not scheduled, but many compounders also handle scheduled substances and DEA registration signals regulatory seriousness).
3. PCAB accreditation or 503B registration with the FDA. Confirm at FDA's outsourcing facility list.
4. Independent CoA for your specific lot: HPLC purity ≥98%, endotoxin <5 EU/mg, sterility pass per USP <71>.
5. Labeled concentration matches prescribed dose. Tesamorelin is typically prescribed at 1-2 mg/day subcutaneously for its approved indication. Off-label concentrations vary widely; mislabeled concentrations have been a documented problem in FDA inspections.
6. No claims of FDA approval for off-label use. If a pharmacy's website says tesamorelin is "FDA-approved for body composition" or "anti-aging," that is a false claim and a regulatory red flag.
7. Refrigeration-verified shipping. Tesamorelin degrades outside the cold chain. Shipments should arrive with temperature monitors and ice packs, and the pharmacy should replace any shipment that breached temperature.

What "Legality" Actually Means for Your Pharmacy

"Is tesamorelin legal?" is the wrong question. The better question is: does this specific pharmacy have legal authority to compound this specific drug for this specific patient? Given tesamorelin's approved-drug status and its absence from the 503B bulk list, the honest answer at most compounders is "it depends on how aggressively the FDA decides to enforce on any given month." The FDA's enforcement discretion policy for compounded drugs has shifted multiple times since 2020, and there is no guarantee that a pharmacy operating today under enforcement forbearance will be operating next quarter.

The Evidence Gap: What We Do Not Know About Tesamorelin in Women

Women are underrepresented in GH-axis research generally. The key tesamorelin trials enrolled predominantly male HIV-positive patients. Falutz et al. 2010 in NEJM enrolled 412 patients; the proportion of women was not the primary stratification variable and female-specific results were not separately powered. Off-label use in postmenopausal or perimenopausal women therefore rests on extrapolation from a male-predominant HIV population, which is a substantial evidence gap.

Specific unknowns for women include:

• How concurrent systemic hormone therapy (oral versus transdermal estradiol) modifies IGF-1 response
• Whether tesamorelin affects menstrual cycle regularity or ovarian reserve markers in reproductive-age women
• Long-term breast tissue effects at sustained IGF-1 elevations, given IGF-1's established role in breast cell proliferation per published receptor biology data
• Safety in PCOS, a condition that affects roughly 8-13% of reproductive-age women globally
• Whether bone density benefits observed in GH-deficient men translate to postmenopausal women already at elevated fracture risk

Any clinician prescribing tesamorelin off-label to women should be transparent about these unknowns. If they are not, that is a clinical concern.

Monitoring If You and Your Clinician Proceed

Monitoring is not optional. These are the labs your prescriber should order before starting and at regular intervals:

| Parameter | Baseline | 3 months | 6 months | |---|---|---|---| | IGF-1 | Yes | Yes | Yes | | Fasting glucose | Yes | Yes | Yes | | HbA1c | Yes | No | Yes | | Fasting insulin | Yes | No | Yes | | Lipid panel | Yes | No | Yes | | Thyroid (TSH, free T4) | Yes | No | Yes | | Cortisol (morning) | Yes | No | If symptomatic |

Tesamorelin can worsen glucose tolerance. The FDA-approved prescribing information notes that patients with diabetes or impaired glucose tolerance should be monitored closely. Women in perimenopause already face increasing insulin resistance as estrogen declines; combining tesamorelin with that hormonal backdrop warrants more frequent glucose monitoring than the standard protocol above.

Thyroid monitoring matters because GH stimulation can accelerate conversion of T4 to T3, potentially unmasking subclinical hypothyroidism. Women have roughly a 5-8 times higher lifetime risk of thyroid disease than men, making this monitoring point especially relevant.